MDM2 and cancer: p53 reactivation by MDM2 inhibitors sensitizes p53 wild-type cancer cells to DNA damaging agents, which trigger the intrinsic pathway of apoptosis, or to extrinsic apoptosis activators such as TRAIL (Tumor necrosis factor (TNF)-related apoptosis-inducing ligand) [14–17].